Zürcher Kantonalbank (‘ZKB’) priced its inaugural CHF 425 m Bail-in Bond issuance. ZKB’s Bail-in Bonds are novel instruments which have been designed and issued on the basis of a new legal framework allowing Cantonal
Search Results for: Homburger
Homburger advised allosteric modulation company Addex Therapeutics in Plan-les-Ouates, Geneva (SIX: ADXN) in the completion of an equity financing transaction with a healthcare-focused institutional investor, pursuant to which Addex agreed to sell 7,999,998 shares
Solenis has announced that it has entered into a definitive merger agreement under which Solenis will acquire Diversey in an all-cash transaction valued at an enterprise value of approximately USD 4.6 billion. Upon completion of the
Swiss law firm Homburger acted as legal counsel to Zürcher Kantonalbank, which served as the mandated lead arranger, agent, security agent and original lender, as well as Credit Suisse (Switzerland) and Migros Bank, acting
Credit Suisse and UBS signed a merger agreement, with UBS emerging as the surviving entity. With the combined market capitalization is approximately USD 65 billion, the merger follows negotiations between the two Swiss banks, prompted by
Legal advisors involved in the UBS-Credit Suisse merger: For UBS: Freshfields Bruckhaus Deringer (‘Freshfields’) is advising UBS Group as global transaction counsel. UBS counsel also include Bär & Karrer and Davis Polk. For Credit
Nestlé Holdings, Inc. recently wrapped up a noteworthy financial transaction with the assistance of Homburger, a trusted legal advisor. The deal involved the issuance of a total of USD 3 billion in notes through an institutional (
Roche Finance Europe issued EUR 1.25 bn Bonds guaranteed by Roche Holding on February 27, 2023. The transaction consists of a EUR 750 m tranche due August 2029 and a EUR 500 m tranche due February 2035. Banco Santander, Barclays Bank and
Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system disorders, successfully closed an oversubscribed Series B financing round, raising CHF 103 mio (approx. USD 112 mio). The round was co-led by the European healthcare focused
Santhera Pharmaceuticals Holding announced a private placement of shares and an amendment of its existing financing with funds managed by Highbridge Capital Management to provide up to CHF 22.2 million in aggregate, subject to certain milestones
